Curis, Inc. – NASDAQ:CRIS
Curis stock price today
$1.63
-1.62
-49.85%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Curis stock price monthly change
-53.17%
month
Curis stock price quarterly change
-53.17%
quarter
Curis stock price yearly change
-76.95%
year
Curis key metrics
Market Cap | 29.63M |
Enterprise value | 55.48M |
P/E | -1.23 |
EV/Sales | 5.46 |
EV/EBITDA | -1.07 |
Price/Sales | 7.00 |
Price/Book | 1.52 |
PEG ratio | 0.05 |
EPS | -8.69 |
Revenue | 9.81M |
EBITDA | -48.90M |
Income | -47.79M |
Revenue Q/Q | -9.18% |
Revenue Y/Y | -5.67% |
Profit margin | -557.69% |
Oper. margin | -521.75% |
Gross margin | 97.47% |
EBIT margin | -521.75% |
EBITDA margin | -498.4% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCuris stock price history
Curis stock forecast
Curis financial statements
| Jun 2023 | 2.19M | -11.96M | -544.42% |
|---|---|---|---|
| Sep 2023 | 2.83M | -12.18M | -429.97% |
| Dec 2023 | 2.69M | -11.78M | -436.94% |
| Mar 2024 | 2.08M | -11.87M | -569.32% |
| Mar 2024 | 2.08M | -11.87M | -569.32% |
|---|---|---|---|
| Sep 2025 | 2.91M | -6.43M | -220.79% |
| Oct 2025 | 2.91M | -6.50M | -223.21% |
| Dec 2025 | 2.85M | -4.19M | -147.13% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 84308000 | 58.08M | 68.9% |
|---|---|---|---|
| Sep 2023 | 89975000 | 60.38M | 67.11% |
| Dec 2023 | 77282000 | 57.61M | 74.55% |
| Mar 2024 | 62024000 | 52.56M | 84.74% |
| Jun 2023 | -7.86M | -3.15M | -852K |
|---|---|---|---|
| Sep 2023 | -8.18M | 180K | 12.55M |
| Dec 2023 | -10.18M | 14.51M | -2.11M |
| Mar 2024 | -13.23M | 18.91M | -2.40M |
Curis alternative data
| Aug 2023 | 51 |
|---|---|
| Sep 2023 | 51 |
| Oct 2023 | 51 |
| Nov 2023 | 51 |
| Dec 2023 | 51 |
| Jan 2024 | 51 |
| Feb 2024 | 51 |
| Mar 2024 | 49 |
| Apr 2024 | 49 |
| May 2024 | 49 |
| Jun 2024 | 49 |
| Jul 2024 | 49 |
Curis other data
38.70%
-8.49%
of CRIS is owned by hedge funds
64
-22
35.46M
-7.78M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2022 | 0 | 5500 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DENTZER JAMES E director, officer.. | Common Stock | 3,094 | $3.07 | $9,499 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 2,406 | $3.18 | $7,651 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 3,094 | $10.59 | $32,759 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 2,283 | $10.96 | $25,022 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 3,094 | $1.64 | $5,077 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 3,658 | $1.69 | $6,182 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 3,094 | $1.16 | $3,577 | ||
Sale | MARTELL ROBERT officer: Head of .. | Common Stock | 5,500 | $1.07 | $5,902 | ||
Sale | DENTZER JAMES E director, officer.. | Common Stock | 2,397 | $1.09 | $2,613 | ||
Sale | GREENACRE MARTYN D director | Common Stock | 18,500 | $1.05 | $19,481 |
| Patent |
|---|
Application Filling date: 21 Dec 2021 Issue date: 11 Aug 2022 |
Application Filling date: 9 Sep 2021 Issue date: 2 Jun 2022 |
Grant Filling date: 10 Sep 2019 Issue date: 1 Feb 2022 |
Application Filling date: 17 Jun 2021 Issue date: 9 Dec 2021 |
Grant Filling date: 7 Jan 2020 Issue date: 5 Oct 2021 |
Application Filling date: 29 Oct 2020 Issue date: 23 Sep 2021 |
Application Filling date: 23 Dec 2020 Issue date: 15 Jul 2021 |
Grant Utility: Crystal forms of immunomodulators Filling date: 27 Sep 2018 Issue date: 22 Jun 2021 |
Application Filling date: 27 Oct 2020 Issue date: 11 Mar 2021 |
Grant Filling date: 12 May 2020 Issue date: 19 Jan 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 8 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. James E. Dentzer (1967) Pres, Chief Executive Officer & Director | $1,040,000 |
| Dr. Robert E. Martell (1963) Head of R&D | $639,450 |
| Mr. William E. Steinkrauss (1986) Chief Financial Officer | $569,860 |
-
What's the price of Curis stock today?
One share of Curis stock can currently be purchased for approximately $1.63.
-
When is Curis's next earnings date?
Unfortunately, Curis's (CRIS) next earnings date is currently unknown.
-
Does Curis pay dividends?
No, Curis does not pay dividends.
-
How much money does Curis make?
Curis has a market capitalization of 29.63M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 1.37% to 10.02M US dollars.
-
What is Curis's stock symbol?
Curis, Inc. is traded on the NASDAQ under the ticker symbol "CRIS".
-
What is Curis's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Curis?
Shares of Curis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Curis's key executives?
Curis's management team includes the following people:
- Mr. James E. Dentzer Pres, Chief Executive Officer & Director(age: 58, pay: $1,040,000)
- Dr. Robert E. Martell Head of R&D(age: 62, pay: $639,450)
- Mr. William E. Steinkrauss Chief Financial Officer(age: 39, pay: $569,860)
-
How many employees does Curis have?
As Jul 2024, Curis employs 49 workers.
-
When Curis went public?
Curis, Inc. is publicly traded company for more then 25 years since IPO on 1 Aug 2000.
-
What is Curis's official website?
The official website for Curis is curis.com.
-
Where are Curis's headquarters?
Curis is headquartered at Building C, Lexington, MA.
-
How can i contact Curis?
Curis's mailing address is Building C, Lexington, MA and company can be reached via phone at +61 75036500.
Curis company profile:
Curis, Inc.
curis.comExchange:
NASDAQ
Full time employees:
49
Industry:
Biotechnology
Sector:
Healthcare
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Building C
Lexington, MA 02421
Lexington, MA 02421
CIK: 0001108205
ISIN: US2312693094
CUSIP: 231269200
